Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBIT (2016 - 2025)

Lipocine (LPCN) has disclosed EBIT for 13 consecutive years, with -$3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 27.77% year-over-year to -$3.4 million, compared with a TTM value of -$5.2 million through Sep 2025, up 2.66%, and an annual FY2024 reading of $1897.0, up 100.01% over the prior year.
  • EBIT was -$3.4 million for Q3 2025 at Lipocine, down from -$2.4 million in the prior quarter.
  • Across five years, EBIT topped out at $9.5 million in Q4 2021 and bottomed at -$7.0 million in Q3 2023.
  • Average EBIT over 5 years is -$2.0 million, with a median of -$3.0 million recorded in 2021.
  • The sharpest move saw EBIT skyrocketed 297.96% in 2021, then tumbled 164.86% in 2025.
  • Year by year, EBIT stood at $9.5 million in 2021, then plummeted by 126.94% to -$2.6 million in 2022, then decreased by 1.27% to -$2.6 million in 2023, then surged by 204.21% to $2.7 million in 2024, then plummeted by 224.37% to -$3.4 million in 2025.
  • Business Quant data shows EBIT for LPCN at -$3.4 million in Q3 2025, -$2.4 million in Q2 2025, and -$2.1 million in Q1 2025.